SCHEMBL802251

SCHEMBL802251

Cc1ccc2c(Nc3nc(C)n[nH]3)nc(-c3ccc(Cl)cc3)nc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.52
AURKB Q96GD4 3/20 0.43
ABCG2 Q9UNQ0 3/20 0.43
PDE5A O76074 1/20 0.43
KDM1A O60341 2/20 0.42
MAPT P10636 3/20 0.41
GSK3B P49841 3/20 0.41
TP53 P04637 2/20 0.41
GSK3A P49840 2/20 0.41
POLB P06746 2/20 0.41
SRC P12931 2/20 0.41
GAA P10253 1/20 0.41
EIF2AK2 P19525 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ABCB1 P08183 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40
NTSR1 P30989 1/20 0.39
GBA1 P04062 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12620400 0.85 AURKA (0.47) AURKAAURKBABCG2PDE5AKDM1A
SCHEMBL802447 0.84 AURKA (0.48) AURKAAURKBABCG2PDE5AMAPT
SCHEMBL802151 0.82 AURKA (0.76) AURKAAURKBGSK3BGSK3ASRC
SCHEMBL13098117 0.81 AURKA (0.43) AURKAAURKBABCG2PDE5AKDM1A
SCHEMBL801831 0.81 AURKA (0.46) AURKAAURKBKDM1AMAPTGSK3B
SCHEMBL802445 0.80 ABCG2 (0.53) AURKAAURKBABCG2PDE5AMAPT
SCHEMBL13107614 0.80 AURKA (0.44) AURKAAURKBABCG2MAPTGSK3B
SCHEMBL801860 0.77 GSK3B (0.62) AURKAAURKBABCG2PDE5AKDM1A
SCHEMBL786303 0.77 GSK3B (0.64) AURKAAURKBABCG2PDE5AMAPT
SCHEMBL10308966 0.76 CYP1A1 (0.52) AURKAPDE5AKDM1AMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 AURKA 8/4885AURKB 19/4885ABCG2 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.